

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
WEX PHARMACEUTICALS INC.	10/15/2009
RECEIVING PARTY DATA	
Name:	WEX MEDICAL LIMITED
Street Address:	Unit A2, 13/F, Loyong Court, 212-220 Lockart Road
City:	Wanchai
State/Country:	HONG KONG
PROPERTY NUMBERS Total: 7	
Property Type	Number
Patent Number:	6478966
Patent Number:	6562968
Patent Number:	6559154
Application Number:	11663358
Application Number:	11990757
Patent Number:	5846975
Application Number:	12294843
CORRESPONDENCE DATA	
Fax Number:	(613)787-3558
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	6132375160
Email:	aarmstrongbaker@blgcanada.com
Correspondent Name:	BORDEN LADNER GERVAIS LLP
Address Line 1:	WORLD EXCHANGE PLAZA
Address Line 2:	100 QUEEN STREET SUITE 1100
Address Line 4:	OTTAWA, CANADA K1P 1J9
ATTORNEY DOCKET NUMBER:	GP 24064-9

CH \$280.00 6478966

501180333

PATENT
REEL: 024402 FRAME: 0748

NAME OF SUBMITTER:

Angie Armstrong-Baker

Total Attachments: 9

source=Wex_Pharmaceuticals_to_Wex_Medical_assignment#page1.tif

source=Wex_Pharmaceuticals_to_Wex_Medical_assignment#page2.tif

source=Wex_Pharmaceuticals_to_Wex_Medical_assignment#page3.tif

source=Wex_Pharmaceuticals_to_Wex_Medical_assignment#page4.tif

source=Wex_Pharmaceuticals_to_Wex_Medical_assignment#page5.tif

source=Wex_Pharmaceuticals_to_Wex_Medical_assignment#page6.tif

source=Wex_Pharmaceuticals_to_Wex_Medical_assignment#page7.tif

source=Wex_Pharmaceuticals_to_Wex_Medical_assignment#page8.tif

source=Wex_Pharmaceuticals_to_Wex_Medical_assignment#page9.tif

WORLDWIDE ASSIGNMENT

WHEREAS, WEX PHARMACEUTICALS INC. ("**Assignor**") having a post office address at 700 West Pender Street, Suite 1601, Vancouver, B.C. Canada V6C 1G8 is the owner and/or registered holder or otherwise entitled to certain intellectual properties rights; and

WHEREAS, it is in the interests of the Assignor to transfer all said intellectual property rights held by the Assignor to WEX MEDICAL LIMITED ("**Assignee**"), having a post office address at Unit A2, 13/F, Loyong Court, 212 – 220 Lockart Road, Wanchai, Hong Kong;

NOW THEREFORE, in exchange for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor hereby sells, assigns and transfers unto said Assignee all of the Assignee's right, title and interest in the inventions disclosed and/or claimed in a patent and/or patent applications set out in the attached Schedule "A" along with the Assignor's right, title and interest in the inventions disclosed and/or claimed in:

- (i) any and all counterparts, patents and/or applications claiming priority from Schedule "A";
- (ii) all corresponding right, title and interest in and to any patent issued from Schedule "A";
- (iii) any patent application and/or patents issued from a continuation, continuation-in-part, re-issue, divisional, re-examination application derived, or claiming priority from those patents and/or patent applications set out in the attached Schedule "A".

This Assignment also includes, without limitation, the right to claim priority based on the filing date of said patents and patent applications herein assigned under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention and all other treaties of like purposes. This Assignment further includes, without limitation, any claims (known or unknown, suspected or unsuspected) of any nature that Assignor has or may have against any party for infringement of any of the patents and patent applications that are assigned herein, and the right to sue for past infringement and to recover and retain damages and profits in respect thereof.


The Assignor and Assignee (the "Parties") further agree that Schedule "A" may be revised as required to give full effect to the Parties intention hereto, and that any such amendments that are agreed to in writing by the Parties will be considered to have retroactive application to the date this Assignment takes effect as noted herein.

The Parties agree that Borden Ladner Gervais LLP is further authorized to insert any further information and/or identification necessary, to ensure recordation of this Assignment in the Patent Offices of any country as may be required. The Parties further agree to take whatever additional actions may be necessary and/or to execute any additional documentation that may be required so as to implement the terms of this Assignment, and permit recordation of any documents that may be required to perfect the Parties intention as outlined herein.

This Assignment shall be effective as of October 15, 2009, and the Parties intention is that the Assignment shall be effective as of this date irrespective of any laws or requirements imposed by any jurisdiction or Patent Office, including any provisions that may provide for a different effective date of transfer.

WEX PHARMACEUTICALS INC.

WEX MEDICAL LIMITED

By 

By: 

Name: Kwong Choo

Name Bin Huang

Title: Chief Financial Officer and Vice President, Finance and Administration

Title President & Chief Executive Officer

Date: October 15, 2009

Date: October 15, 2009


STATEMENT BY WITNESS

I, Judy Lam, whose full post office address is _____
(name of witness)

1601-700 W. Pender ST, Van BC V6C 1G8

was personally present and did see Kwong Choo execute the within Assignment and who is personally known to me to be the person signing such document.

Signature of Witness




STATEMENT BY WITNESS

I, Judy Lam, whose full post office address is _____
(name of witness)

1601-700 W. Pender ST. Van, BC V6C 1G8

was personally present and did see Bin Huang execute the within Assignment and who is personally known to me to be the person signing such document.

Signature of Witness



SCHEDULE "A"

Current Owner	Title	Country	Status	Client Reference	Serial Number	Filing Date	BLG File Number	
Wex Pharmaceuticals Inc.	THE USE OF AMINO HYDROGENATED QUINAZOLINE COMPOUNDS AND DERIVATIVES FOR ABSTAINING FROM DRUG DEPENDENCE	Germany	Issued/Reg	800DE	95911187.3	11-03-1995	PAT	100100WEP-6
Wex Pharmaceuticals Inc..	THE USE OF AMINO HYDROGENATED QUINAZOLINE COMPOUNDS AND DERIVATIVES FOR ABSTAINING FROM DRUG DEPENDENCE	France	Issued/Reg	800FR	95911187.3	11-03-1995	PAT	100100WEP-5
Wex Pharmaceuticals Inc.	THE USE OF AMINO HYDROGENATED QUINAZOLINE COMPOUNDS AND DERIVATIVES FOR ABSTAINING FROM DRUG DEPENDENCE	United Kingdom	Issued/Reg	800GB	95911187.3	11-03-1995	PAT	100100WEP-3
Wex Pharmaceuticals Inc.	A SYSTEM FOR EXTRACTING TETRODOTOXIN	Portugal	Issued/Reg	804PT	242307	19-11-2001	PAT	100104W-61
Wex Pharmaceuticals Inc	SYSTEM FOR EXTRACTING TETRODOTOXIN	United States	Issued/Reg	804US	09/818,775	28-03-2001	PAT	100104-2
Wex Pharmaceuticals Inc.	A METHOD OF PURIFYING TETRODOTOXIN	Portugal	Issued/Reg	805PT	0242308	19-11-2001	PAT	100105W-61
Wex Pharmaceuticals Inc	METHOD OF PURIFYING TETRODOTOXIN	United States	Issued/Reg	805US	09/818,863	28-03-2001	PAT	100105-2
Wex Pharmaceuticals Inc	A COMPOSITION OF SODIUM CHANNEL BLOCKING COMPOUND	Europe	Issued/Reg	806EP	01997312.2	19-11-2001	PAT	100106WEP-81

Current Owner	Title	Country	Status	Client Reference	Serial Number	Filing Date	BLG File Number	
Wex Pharmaceuticals Inc	A COMPOSITION OF SODIUM CHANNEL BLOCKING COMPOUND	United Kingdom	Issued/Reg	806GB	01997312.2	19-11-2001	PAT	100106WEP-3
Wex Pharmaceuticals Inc.	COMPOSITION OF SODIUM CHANNEL BLOCKING COMPOUND	United States	Issued/Reg	806US	09/819,796	29-03-2001	PAT	100106-2
Wex Pharmaceuticals Inc.	STABLE FREEZE-DRIED PHARMACEUTICAL FORMULATION OF TETRODOTOXIN	Canada	Pending	809CA	2,529,598	02-07-2004	PAT	100108W-1
Wex Pharmaceuticals Inc.	STABLE TETRODOTOXIN FREEZE DRYING MEDICINAL PREPARATION	European Community	Pending	809EP	04737334.4	02-07-2004	PAT	100108WEP-81
Wex Pharmaceuticals Inc.	STABLE FREEZE-DRIED PHARMACEUTICAL FORMULATION OF TETRODOTOXIN	India	Pending	809IN	5833/DELNP/2005	02-07-2004	PAT	100108W-19
Wex Pharmaceuticals Inc.	STABLE TETRODOTOXIN FREEZE DRYING MEDICINAL PREPARATION	Korea	Published	809KR	10-2006-7000851	02-07-2004	PAT	100108W-68
Wex Pharmaceuticals Inc.	STABLE PHARMACEUTICAL COMPOSITION OF FREEZE-DRIED TETRODOTOXIN POWDER	United States	Allowed	809US	10/890,279	14-07-2004	PAT	100108-2
Wex Pharmaceuticals Inc.	TETRODOTOXIN AND ITS DERIVATIVES FOR THE TREATMENT OF CENTRAL-NERVOUSLY DERIVED NEUROPATHIC PAIN	Australia	Pending	815AU1	2005287511	21-09-2005	PAT	100114W-4

Current Owner	Title	Country	Status	Client Reference	Serial Number	Filing Date	BLG File Number	
Wex Pharmaceuticals Inc.	TETRODOTOXIN AND ITS DERIVATIVES FOR THE TREATMENT OF PERIPHERAL-NEUROUSLY DERIVED NEUROPATHIC PAIN	Australia	Pending	815AU2	2005287580	20-09-2005	PAT	100129W-4
Wex Pharmaceuticals Inc.	TETRODOTOXIN AND ITS DERIVATIVES FOR THE TREATMENT OF CENTRAL-NEUROUSLY DERIVED NEUROPATHIC PAIN	Canada	Pending	815CA1	2,581,128	21-09-2005	PAT	100114W-1
Wex Pharmaceuticals Inc.	TETRODOTOXIN AND ITS DERIVATIVES FOR THE TREATMENT OF PERIPHERAL-NEUROUSLY DERIVED NEUROPATHIC PAIN	Canada	Pending	815CA2	2,581,083	20-09-2005	PAT	100129W-1
Wex Pharmaceuticals, Inc.	TETRODOTOXIN AND ITS DERIVATIVES FOR THE TREATMENT OF CENTRAL-NEUROUSLY DERIVED NEUROPATHIC PAIN	China	Published	815CN1	200580031751.9	21-09-2005	PAT	100114W-80
Wex Pharmaceuticals, Inc.	TETRODOTOXIN AND ITS DERIVATIVES FOR THE TREATMENT OF PERIPHERAL-NEUROUSLY DERIVED NEUROPATHIC PAIN	China	Pending	815CN2	200580031979.8	20-09-2005	PAT	100129W-80
Wex Pharmaceuticals Inc.	TETRODOTOXIN AND ITS DERIVATIVES FOR THE TREATMENT OF CENTRAL-NEUROUSLY DERIVED NEUROPATHIC PAIN	European Community	Pending	815EP1	05794395.3	21-09-2005	PAT	100114WEP-81

Current Owner	Title	Country	Status	Client Reference	Serial Number	Filing Date	BLG File Number	
Wex Pharmaceuticals Inc.	TETRODOTOXIN AND ITS DERIVATIVES FOR THE TREATMENT OF PERIPHERAL-NEUROUSLY DERIVED NEUROPATHIC PAIN	European Community	Pending	815EP2	05802223.7	20-09-2005	PAT	100129WEP-81
Wex Pharmaceuticals Inc.	TETRODOTOXIN AND ITS DERIVATIVES FOR THE TREATMENT OF CENTRAL-NEUROUSLY DERIVED NEUROPATHIC PAIN	Hong Kong	Published	815HK1	07113465.2	21-09-2005	PAT	100114WEP-51
Wex Pharmaceuticals Inc.	TETRODOTOXIN AND ITS DERIVATIVES FOR THE TREATMENT OF PERIPHERAL-NEUROUSLY DERIVED NEUROPATHIC PAIN	Hong Kong	Published	815HK2	07113468.9	20-09-2005	PAT	100129WEP-51
Wex Pharmaceuticals Inc.	TETRODOTOXIN AND ITS DERIVATIVES FOR THE TREATMENT OF CENTRAL-NEUROUSLY DERIVED NEUROPATHIC PAIN	Korea	Pending	815KR1	10-2007-7008176	21-09-2005	PAT	100114W-68
Wex Pharmaceuticals Inc.	TETRODOTOXIN AND ITS DERIVATIVES FOR THE TREATMENT OF PERIPHERAL-NEUROUSLY DERIVED NEUROPATHIC PAIN	Korea	Pending	815KR2	10-2007-7008182	20-09-2005	PAT	100129W-68
Wex Pharmaceuticals Inc.	TETRODOTOXIN AND ITS DERIVATIVES FOR THE TREATMENT OF CENTRAL-NEUROUSLY DERIVED NEUROPATHIC PAIN	United States	Published	815US1	11/663,268	21-09-2005	PAT	100114W-2

Current Owner	Title	Country	Status	Client Reference	Serial Number	Filing Date	BLG File Number	
Wex Pharmaceuticals Inc.	TETRODOTOXIN AND ITS DERIVATIVES FOR THE TREATMENT OF PERIPHERAL-NEUROUSLY DERIVED NEUROPATHIC PAIN	United States	Published	815US2	11/663,358	20-09-2005	PAT	100129W-2
Wex Pharmaceuticals Inc.	USE OF SODIUM CHANNEL BLOCKERS FOR THE MANAGEMENT OF MUSCULOSKELETAL PAIN	United States	Published	820US	11/990,757	25-08-2006	PAT	100119W-2
Wex Pharmaceuticals Inc.	USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF VISCERAL PAIN OR PAIN CAUSED BY CANCER TREATMENT	Canada	Pending	821CA	2,619,856	25-08-2006	PAT	100120W-1
Wex Pharmaceuticals Inc.	USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF VISCERAL PAIN OR PAIN CAUSED BY CANCER TREATMENT	European Community	Published	821EP	06802402.5	25-08-2006	PAT	100120WEP-81
Wex Pharmaceuticals Inc.	USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF VISCERAL PAIN OR PAIN CAUSED BY CANCER TREATMENT	United States	Published	821US	11/990,743	25-08-2006	PAT	100120W-2
Wex Pharmaceuticals Inc.	USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY	Canada	Pending	828CA	2,647,235	26-03-2007	PAT	100131W-1

Current Owner	Title	Country	Status	Client Reference	Serial Number	Filing Date	BLG File Number	
Wex Pharmaceuticals Inc.	USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY	China	Pending	828CN	200780011388.3	26-03-2007	PAT	100131W-80
Wex Pharmaceuticals Inc.	USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY	European Community	Published	828EP	07723608.1	26-03-2007	PAT	100131WEP-81
Wex Pharmaceuticals Inc.	USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY	United States	Pending	828US	12/294,843	26-03-2007	PAT	100131W-2
Wex Pharmaceuticals Inc. (formerly International Wex Technologies Inc.)	USE OF AMINO HYDROGENATED QUINAZOLINE COMPOUNDS AND DERIVATIVES THEREOF FOR ABSTAINING FROM DRUG DEPENDENCE	United States	Issued/Reg	800US	08/640,781	11-03-1995	PAT	100100W-2